Role of astrocyte-based cholinergic neuromodulation in cognition and in the treatment of cognitive disorders
基于星形胶质细胞的胆碱能神经调节在认知和认知障碍治疗中的作用
基本信息
- 批准号:10403565
- 负责人:
- 金额:$ 39.38万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-06-01 至 2026-03-31
- 项目状态:未结题
- 来源:
- 关键词:AdultAgonistAstrocytesBehaviorBehavioralBenchmarkingBindingBiologyBrainBrain DiseasesCellsCharacteristicsClinicalClinical TreatmentClinical TrialsCodeCognitionCognition DisordersCognitiveCognitive deficitsCouplingCrystallizationCuesDataDoseElectron MicroscopyEnvironmentFDA approvedFailureFluorescenceGeneticHumanImpaired cognitionInterventionKnockout MiceLigandsLightLinkMATRICS Consensus Cognitive BatteryMapsMeasuresMediatingMental HealthMental disordersModalityMolecularMorphologyMusNational Institute of Mental HealthNeurobehavioral ManifestationsNeurogliaNeuronsNeurophysiology - biologic functionNootropic AgentsOutputPathway interactionsPatientsPharmaceutical PreparationsPharmacologic SubstancePhase III Clinical TrialsPilot ProjectsPositioning AttributeProcessQuantum DotsResearchRoleRouteSchizophreniaSeminalSerineShapesSignal TransductionSurfaceSynapsesTestingTherapeuticWorkalpha-bungarotoxin receptorbasebehavioral outcomecell typecholinergiccognitive disabilitycognitive enhancementcognitive functiondrinking waterdrug developmentexcitatory neuronimaging studyin vivoinhibitory neuronnanoscalenervous system disorderneural circuitneuroregulationparticleprogramsreceptorresponsestimulant usesuccesstherapeutic evaluation
项目摘要
ABSTRACT
Neurons are viewed as the cellular correlate of cognition and only target of clinical therapeutics, in part because
manipulating neurons rapidly and directly alters behavior. Yet, the human brain is also made of glial cells, which
morphological and genetic complexification is a striking feature of the human brain. Astrocytes, in particular, are
now known to orchestrate many neural functions, crystalizing the possibility of a direct astrocyte contribution to
cognitive functions and mental health. However, a lack of understanding of the rules that govern astrocytes
activity and their involvement in neural circuits has limited our ability to test this idea. Collective work recently
showed that astrocytes transduce neuromodulatory information onto synaptic circuits. Specifically, we found that
α7 nicotinic acetylcholine receptors (α7nAChRs) on astrocytes regulate the release of the astrocyte transmitter
D-serine onto synapses. Neuromodulation, in particular cholinergic signaling, permits behavioral adaptations to
changes in the environment, and its alteration is linked to cognitive deficits in schizophrenia. Coincidently, the
α7nAChR has focalized major drug development efforts in the past decade to restore the cognitive symptoms of
patients with schizophrenia. Here, we will take advantage of this new astrocyte-based α7nAChR pathway to test
the role of astrocytes in cognitive functions and pro-cognitive interventions, and elucidate the mechanisms
through which neuromodulation is sensed and transduced by astrocytes at the cellular and molecular levels. In
doing so, we will test a set of general principles which we hypothesize govern input output fidelity in astrocytes
(positional coupling). In Aim 1, we will test the hypothesis that α7nAChRs are located in the immediate vicinity
of D-serine pools, directly linking Ca2+ influx through α7nAChR channel activity to the Ca2+-dependent D-serine
release machinery. We will conduct fluorescence Ca2+ imaging studies to understand the spatial, temporal and
molecular rules of α7nAChR-mediated Ca2+ signals and their relation to D-serine release. We will then map the
physical association of α7nAChR and D-serine pools in perisynaptic astrocytic processes, using electron
microscopy. In addition, we will conduct single-particle tracking studies to understand how the dynamic
distribution of α7nAChR at the surface of astrocytes, with respect to D-serine pools, is influenced by the binding
of endogenous and exogenous ligands. In Aim 2, we will generate cell-specific knockout mouse lines to
selectively ablate α7nAChR from astrocytes, excitatory neurons or inhibitory neurons in the brain, and canvas
the contribution of each cell-types to characteristic behaviors supported by α7nAChRs. We recently showed that
an α7nAChR partial agonist tested in Phase-III clinical trials for the treatment of cognitive deficits in patients with
schizophrenia, elevates D-serine levels in the mouse brain. Based on our observations that inactivating
astrocyte-based α7nAChR signaling leads to specific alterations in D-serine levels and cognitive behavior, we
will then test the hypothesis that astrocytes, but not neurons, enable the behavioral efficacy of cognitive
enhancers tested in clinical trials, and that D-serine signaling is the circuit actuator of these effects.
摘要
神经元被视为认知的细胞关联,也是临床治疗的唯一目标,部分原因是
快速而直接地操纵神经元可以改变行为。然而,人类的大脑也是由胶质细胞组成的,它
形态和遗传的复杂化是人脑的一个显著特征。尤其是星形胶质细胞,
现在已知协调许多神经功能,明确了星形胶质细胞直接贡献的可能性
认知功能和心理健康。然而,由于缺乏对星形胶质细胞规则的理解
活动和它们对神经回路的参与限制了我们测试这一想法的能力。最近的集体工作
表明星形胶质细胞将神经调节信息传递到突触回路。具体来说,我们发现,
星形胶质细胞上α7烟碱型乙酰胆碱受体(α7nAChRs)调节星形胶质细胞递质的释放
D-丝氨酸进入突触。神经调节,特别是胆碱能信号,允许行为适应
环境的变化,以及它的变化与精神分裂症的认知缺陷有关。巧合的是,
α7nAChR在过去十年中专注于主要药物开发努力,以恢复
精神分裂症患者。在这里,我们将利用这一基于星形胶质细胞的新的α7nAChR途径来测试
星形胶质细胞在认知功能和前认知干预中的作用,并阐明其机制
通过它,星形胶质细胞在细胞和分子水平上感受和传递神经调节。在……里面
这样做,我们将测试一组我们假设的支配星形胶质细胞输入输出保真度的一般原则
(位置联轴器)。在目标1中,我们将检验α7nAChRs位于邻近区域的假设
在D-丝氨酸库中,通过α7nAChR通道活性将钙离子内流直接连接到钙依赖的D-丝氨酸
释放机械。我们将进行荧光钙成像研究,以了解空间,时间和
α7nAChR介导的钙信号的分子规律及其与D-丝氨酸释放的关系然后,我们将绘制
突触周围星形细胞突起中α7nAChR和D-丝氨酸池的物理联系
显微镜。此外,我们将进行单粒子跟踪研究,以了解
α7nAChR在星形胶质细胞表面相对于D-丝氨酸池的分布受结合的影响
内源和外源配体。在目标2中,我们将生成细胞特异性基因敲除小鼠系来
选择性消融星形胶质细胞、脑内兴奋性神经元或抑制性神经元和画布中的α7nAChR
每种细胞类型对α7nAChRs支持的特征行为的贡献。我们最近展示了
一种α7nAChR部分激动剂在第三阶段临床试验中用于治疗慢性阻塞性肺疾病患者的认知障碍
精神分裂症,会提高小鼠大脑中D-丝氨酸的水平。根据我们的观察,灭活
基于星形胶质细胞的α7nAChR信号导致D-丝氨酸水平和认知行为的特定变化
然后将检验这一假设,即星形胶质细胞,而不是神经元,使认知的行为效能
增强剂在临床试验中进行了测试,D-丝氨酸信号是这些效应的电路执行器。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Thomas Papouin其他文献
Thomas Papouin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Thomas Papouin', 18)}}的其他基金
Role of astrocyte-based cholinergic neuromodulation in cognition and in the treatment of cognitive disorders
基于星形胶质细胞的胆碱能神经调节在认知和认知障碍治疗中的作用
- 批准号:
10280174 - 财政年份:2021
- 资助金额:
$ 39.38万 - 项目类别:
Role of astrocyte-based cholinergic neuromodulation in cognition and in the treatment of cognitive disorders
基于星形胶质细胞的胆碱能神经调节在认知和认知障碍治疗中的作用
- 批准号:
10589881 - 财政年份:2021
- 资助金额:
$ 39.38万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 39.38万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 39.38万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 39.38万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 39.38万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 39.38万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 39.38万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 39.38万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 39.38万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 39.38万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 39.38万 - 项目类别: